Regular blood tests and clinical markers are monitored to assess inflammation levels, metabolic health and overall response to peptide therapy
Until such evidence becomes available, peptide therapy remains a personalized medical decision requiring expert guidance and careful consideration
Cagrilintide has a half-life of about 78 days (roughly 159195 hours measured in a Phase 1b study), and tirzepatide about 5 days (approximately 120 hours)
We offer free consultations for new patients and are ready to help you achieve your weight loss goals in a safe, physician-directed environment
Improved heart health: HGF/c-Met signaling has roles beyond the brain, including cardiovascular tissue a secondary area of observed benefit
Wang W, Li Q, Zhang J, Wu H, Yin Y, Ge Q, Zhang Y